Search

Your search keyword '"Vergnenegre, Alain"' showing total 262 results
Start Over Author "Vergnenegre, Alain"
262 results on '"Vergnenegre, Alain"'

1. A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA–B GFPC 04-2020Study)

Author

Jacob, Mathilde, Fournel, Pierre, Tissot, Claire, Cadranel, Jacques, Bylicki, Olivier, Monnet, Isabelle, Justeau, Grégoire, Ricordel, Charles, Thomas, Pascal, Falchero, Lionel, Locher, Chrystel, Wislez, Marie, Vergnenegre, Alain, Abdiche, Samir, Guisier, Floran, Bizieux, Acya, Lamy, Regine, François, Geraldine, De Chabot, Gonzagues, Pierret, Thomas, Sabatini, Marie, Abeillera, Marion, Vieillot, Sabine, Martinez, Stephanie, Morel, Hugues, Doubre, Hélène, Madroszyk, Anne, Geier, Margaux, LucLabourey, Jean, Chouaïd, Christos, and Greillier, Laurent

Published
2024
Full Text
View/download PDF

2. Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study)

Author

Amari, Lyria, Tomasini, Pascale, Dantony, Emmanuelle, Rousseau-Bussac, Gaelle, Ricordel, Charles, Bigay-Game, Laurence, Arpin, Dominique, Morel, Hugues, Veillon, Remi, Justeau, Grégoire, Huchot, Eric, Fournel, Pierre, Vergnenegre, Alain, Bizeux, Acya, Subtil, Fabien, Clarisse, Bénédicte, Decroisette, Chantal, Chouaid, Christos, Greillier, Laurent, and Bylicki, Olivier

Published
2024
Full Text
View/download PDF

3. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Author

Karachaliou, Niki, Codony-Servat, Jordi, Teixidó, Cristina, Pilotto, Sara, Drozdowskyj, Ana, Codony-Servat, Carles, Giménez-Capitán, Ana, Molina-Vila, Miguel Angel, Bertrán-Alamillo, Jordi, Gervais, Radj, Massuti, Bartomeu, Morán, Teresa, Majem, Margarita, Felip, Enriqueta, Carcereny, Enric, García-Campelo, Rosario, Viteri, Santiago, González-Cao, María, Morales-Espinosa, Daniela, Verlicchi, Alberto, Crisetti, Elisabetta, Chaib, Imane, Santarpia, Mariacarmela, Luis Ramírez, José, Bosch-Barrera, Joaquim, Felipe Cardona, Andrés, de Marinis, Filippo, López-Vivanco, Guillermo, Miguel Sánchez, José, Vergnenegre, Alain, Sánchez Hernández, José Javier, Sperduti, Isabella, Bria, Emilio, and Rosell, Rafael

Published
2023
Full Text
View/download PDF

4. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Author

Abdel-Karim, Isam, Abdelsalam, Mahmoud, Addeo, Alfredo, Aguado, Carlos, Alexander, Patrick, Alt, Jürgen, Azzi, Georges, Balaraman, Rama, Biesma, Bonne, Blackhall, Fiona, Bohnet, Sabine, Boleti, Ekaterini, Borghaei, Hossein, Bradbury, Penelope, Brighenti, Matteo, Campbell, Nicholas, Campbell, Toby, Canon, Jean-Luc, Cappuzzo, Federico, Costa, Enric Carcereny, Cavanna, Luigi, Cetnar, Jeremy, Chella, Antonio, Chouaid, Christos, Christoph, Daniel, Castán, Javier Cortés, Dakhil, Shaker, de Castro Carpeño, Francisco Javier, de Marinis, Filippo, Delmonte, Angelo, Demedts, Ingel, Demey, Wim, Dits, Joyce, del Pilar Diz Taín, Maria, Gómez, Manuel Dómine, Dorius, Timothy, Dumoulin, Daphne, Duruisseaux, Michaël, Eaton, Keith, González, Emilio Esteban, Evans, Devon, Faehling, Martin, Farrell, Nicholas, Feinstein, Trevor, Font, Enriqueta Felip, Garcia Campelo, Maria Rosario, Garon, Edward, Garrido López, María Pilar, Germonpré, Paul, Gersten, Todd, Cao, Maria Gonzalez, Gopaluni, Srivalli, Greillier, Laurent, Grossi, Francesco, Guisier, Florian, Gurubhagavatula, Sarada, Calderón, Vanesa Gutiérrez, Hakimian, David, Hall, Richard, Jr., Hao, Desirée, Harris, Ronald, Hashemi, Sayed, He, Kai, Hendriks, Lizza, Huang, Chao, Ibrahim, Emad, Jain, Sharad, Johnson, Melissa, Jones, Benjamin, Jones, Monte, Juan Vidal, Óscar José, Juergens, Rosalyn, Kaderbhai, Courèche, Kastelijn, Elisabeth A (Lisanne), Keresztes, Roger, Kio, Ebenezer, Kokowski, Konrad, Konduri, Kartik, Kulkarni, Swati, Kuon, Jonas, Kurkjian, Carla, Labbé, Catherine, Lerner, Rachel, Lim, Farah, Madroszyk-Flandin, Anne, Marathe, Omkar, Martincic, Danko, McClay, Edward, McIntyre, Kristi, Mekhail, Tarek, Misino, Andrea, Molinier, Olivier, Morabito, Alessandro, Morócz, Éva, Müller, Veronika, Nagy, Tünde, Nguyen, Anthony V., Nidhiry, Emmanuel, Okazaki, Ian, Ortega-Granados, Ana Laura, Ostoros, Gyula, Oubre, David, Owen, Scott, Pachipala, Krishna, Park, David, Patel, Pareshkumar, Percent, Ivor, Pérol, Maurice, Peters, Solange, Piet, Berber, Planchard, David, Polychronis, Andreas, Aix, Santiago Ponce, Pons-Tostivint, Elvire, Popat, Sanjaykumar, Pulla, Mariano Provencio, Quantin, Xavier, Quéré, Gilles, Rafique, Noman, Ramaekers, Ryan, Reck, Martin, Reiman, Anthony, Reinmuth, Niels, Reynolds, Craig, Rodríguez-Abreu, Delvys, Romano, Gianpiero, Roque, Tammy, Salzberg, Matthew, Sanborn, Rachel, Sandiego, Sergio, Schaefer, Eric, Schreeder, Marshall, Seetharamu, Nagashree, Seneviratne, Lasika, Shah, Purvi, Shunyakov, Leonid, Slater, Dennis, Parra, Hector Soto, Stigt, Johannes, Stilwill, Joseph, Su, Jingdong, Surmont, Veerle, Swink, Alicia, Szalai, Zsuzsanna, Talbot, Toby, Garcia, Alvaro Taus, Theelen, Willemijn, Thompson, Jonathan, Tiseo, Marcello, Uprety, Dipesh, Uyeki, James, van der Leest, Kornelius Cor, Van Ho, Anthony, van Putten, John, Estévez, Sergio Vázquez, Veatch, Andrea, Vergnenègre, Alain, Ward, Patrick, Weise, Amy, Weiss, Matthias, Whitehurst, Matthew, Zai, Silvia, Zalcman, Gérard, Zuniga, Richard, Borghaei, H., de Marinis, F., Dumoulin, D., Reynolds, C., Theelen, W.S.M.E., Percent, I., Gutierrez Calderon, V., Johnson, M.L., Madroszyk-Flandin, A., Garon, E.B., He, K., Planchard, D., Reck, M., Popat, S., Herbst, R.S., Leal, T.A., Shazer, R.L., Yan, X., Harrigan, R., and Peters, S.

Published
2024
Full Text
View/download PDF

6. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Author

Paz-Ares, Luis G., Ramalingam, Suresh S., Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Urban, Laszlo, Caro, Reyes Bernabe, Park, Keunchil, Sakai, Hiroshi, Ohe, Yuichiro, Nishio, Makoto, Audigier-Valette, Clarisse, Burgers, Jacobus A., Pluzanski, Adam, Sangha, Randeep, Gallardo, Carlos, Takeda, Masayuki, Linardou, Helena, Lupinacci, Lorena, Lee, Ki Hyeong, Caserta, Claudia, Provencio, Mariano, Carcereny, Enric, Otterson, Gregory A., Schenker, Michael, Zurawski, Bogdan, Alexandru, Aurelia, Vergnenegre, Alain, Raimbourg, Judith, Feeney, Kynan, Kim, Sang-We, Borghaei, Hossein, O'Byrne, Kenneth John, Hellmann, Matthew D., Memaj, Arteid, Nathan, Faith Ellen, Bushong, Judith, Tran, Phuong, Brahmer, Julie R., and Reck, Martin

Published
2022
Full Text
View/download PDF

7. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Author

Jassem, Jacek, de Marinis, Filippo, Giaccone, Giuseppe, Vergnenegre, Alain, Barrios, Carlos H., Morise, Masahiro, Felip, Enriqueta, Oprean, Cristina, Kim, Young-Chul, Andric, Zoran, Mocci, Simonetta, Enquist, Ida, Komatsubara, Kimberly, McCleland, Mark, Kuriki, Hiroshi, Villalobos, Monette, Phan, See, Spigel, David R., and Herbst, Roy S.

Published
2021
Full Text
View/download PDF

9. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

Author

Baize, Nathalie, Monnet, Isabelle, Greillier, Laurent, Geier, Margaux, Lena, Hervé, Janicot, Henri, Vergnenegre, Alain, Crequit, Jacky, Lamy, Regine, Auliac, Jean-Bernard, Letreut, Jacques, Le Caer, Hervé, Gervais, Radj, Dansin, Eric, Madroszyk, Anne, Renault, Patrick-Aldo, Le Garff, Gwenaëlle, Falchero, Lionel, Berard, Henri, Schott, Roland, Saulnier, Patrick, and Chouaid, Christos

Published
2020
Full Text
View/download PDF

13. Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital

Author

Pinet, Sandra, primary, Durand, Stéphanie, additional, Perani, Alexandre, additional, Darnaud, Léa, additional, Amadjikpe, Fifame, additional, Yon, Mathieu, additional, Darbas, Tiffany, additional, Vergnenegre, Alain, additional, Egenod, Thomas, additional, Simonneau, Yannick, additional, Le Brun-Ly, Valérie, additional, Pestre, Julia, additional, Venat, Laurence, additional, Thuillier, Frédéric, additional, Chaunavel, Alain, additional, Duchesne, Mathilde, additional, Fermeaux, Véronique, additional, Guyot, Anne, additional, Lacorre, Sylvain, additional, Bessette, Barbara, additional, Lalloué, Fabrice, additional, Durand, Karine, additional, and Deluche, Elise, additional

Published
2023
Full Text
View/download PDF

15. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

Author

Chaib, Imane, Karachaliou, Niki, Pilotto, Sara, Codony Servat, Jordi, Cai, Xueting, Li, Xuefei, Drozdowskyj, Ana, Servat, Carles Codony, Yang, Jie, Hu, Chunping, Cardona, Andres Felipe, Vivanco, Guillermo Lopez, Vergnenegre, Alain, Sanchez, Jose Miguel, Provencio, Mariano, de Marinis, Filippo, Passaro, Antonio, Carcereny, Enric, Reguart, Noemi, Campelo, Charo Garcia, Teixido, Cristina, Sperduti, Isabella, Rodriguez, Sonia, Lazzari, Chiara, Verlicchi, Alberto, de Aguirre, Itziar, Queralt, Cristina, Wei, Jia, Estrada, Roger, de la Bellacasa, Raimon Puig, Ramirez, Jose Luis, Jacobsen, Kirstine, Ditzel, Henrik J., Santarpia, Mariacarmela, Viteri, Santiago, Molina, Miguel Angel, Zhou, Caicun, Cao, Peng, Ma, Patrick C., Bivona, Trever G., and Rosell, Rafael

Published
2017
Full Text
View/download PDF

16. A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis

Author

Bechade Clémence, Tivollier Jean-Michel, Cyrille Mathieu, Daures Jean-Pierre, Cécile Couchoud, Anne Ovize, Gabriel Jean-Marc, Halimi Jean Michel, Nguyen Jean-Michel, Bauwens Marc, Wolak Aurore, Testevuide Pascale, Laetitia Koppe, Iacobelli Silvia, Laurence Pellegrina, Mercadal Lucile, Jais Jean-Philippe, Toure Fatouma, Loos-Ayav Carole, Sarraj Ayman, Longlune Nathalie, Sautenent Bénédicte, Laurent Juillard, Cerasuolo Damiano, Gervolino Shirley, Tendron-Franzin Anaïs, Bayat Sahar, Emilie Kalbacher, Glowacki François, Boucaut Maitre Denis, Merle Sylvie, Devictor Bénédicte, Denis Fouque, Ranlin Alex, Maxime Espi, Olivier Thaunat, Chantrel François, Brunet Philippe, Emmanuel Morelon, Salmi Louis Rachid, Virginie Mathias, Monnet Elisabeth, Galland Roula, Edet Stéphane, Kazes Isabelle, Berard Etienne, Lavainne Fréderic, Schauder Nicole, Tiple Aurélien, Courivaud Cécile, Hazzan Marc, Nacher Mathieu, Vacher Coponat Henri, Laurain Emmanuelle, Caroline C. Pelletier, Vergnenegre Alain, Reydit Mathilde, Christine Bouz, Vigneau Cécile, E. Chalencon, Thomas Barba, Xavier Charmetant, Bemrah Abdelkader, Gentile Stéphanie, Merle Véronique, Moranne Olivier, Emmanuelle Cart-Tanneur, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital Edouard Herriot [CHU - HCL], Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Eurofins Biomnis, Université de Lyon, Agence de la biomédecine [Saint-Denis la Plaine], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Registre REIN, École des Hautes Études en Santé Publique [EHESP] (EHESP), REIN Registry: Chantrel François, Reydit Mathilde, Tiple Aurélien, Bechade Clémence, Bemrah Abdelkader, Vigneau Cécile, Sautenent Bénédicte, Kazes Isabelle, Courivaud Cécile, Gabriel Jean-Marc, Edet Stéphane, Mercadal Lucile, Moranne Olivier, Toure Fatouma, Laurain Emmanuelle, Ranlin Alex, Longlune Nathalie, Glowacki François, Tivollier Jean-Michel, Brunet Philippe, Lavainne Fréderic, Berard Etienne, Sarraj Ayman, Bauwens Marc, Testevuide Pascale, Vacher Coponat Henri, Galland Roula, Schauder Nicole, Salmi Louis-Rachid, Cerasuolo Damiano, Tendron-Franzin Anaïs, Bayat Sahar, Halimi Jean Michel, Wolak Aurore, Gentile Stéphanie, Devictor Bénédicte, Monnet Elisabeth, Boucaut Maitre Denis, Nacher Mathieu, Merle Véronique, Jais Jean-Philippe, Daures Jean-Pierre, Vergnenegre Alain, Loos-Ayav Carole, Merle Sylvie, Hazzan Marc, Gervolino Shirley, Nguyen Jean-Michel, Iacobelli Silvia, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and CarMeN, laboratoire

Subjects
medicine.medical_specialty, T cell, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Interferon gamma release assay, Antibodies, Viral, Gastroenterology, Renal Dialysis, Internal medicine, Epidemiology, Medicine, Humans, Clinical Investigation, BNT162 Vaccine, Vaccines, Synthetic, business.industry, SARS-CoV-2, Incidence (epidemiology), COVID-19, Vaccination, [SDV] Life Sciences [q-bio], Titer, medicine.anatomical_structure, mRNA vaccine, Nephrology, Hemodialysis, Cohort, BNT162b2, mRNA Vaccines, business
Abstract

The level of protection achieved by the standard two doses of COVID-19 mRNA vaccines in patients receiving maintenance hemodialysis (MHD) remains unclear. To study this we used the French Renal Epidemiology and Information Network (REIN) Registry to compare the incidence and severity of 1474 cases of COVID-19 diagnosed in patients receiving MHD after none, one or two doses of vaccine. Vaccination significantly reduce COVID-19 incidence and severity but 11% of patients infected after two doses still died. Lack of vaccinal protection in patients naïve for SARS-CoV-2 could be due to defective Tfh response [38% patients with negative spike-specific CD4+ T cell interferon gamma release assay] and failure to generate viral neutralizing titers of anti-spike receptor binding domain (RBD) IgGs (63% patients with titer at or under 997 BAU/ml, defining low/no responders) after two doses of vaccine. To improve protection, a third dose of vaccine was administered to 75 patients [57 low/no responders, 18 high responders after two doses] from the ROMANOV cohort that prospectively enrolled patients receiving MHD vaccinated with BNT162b2 (Pfizer). Tolerance to the third dose was excellent. High responders to two doses did not generate more anti-RBD IgGs after three doses but had more side effects. Importantly, 31 (54%) of low/no responders to two doses reached neutralizing titers of anti-RBD IgGs after three doses. A positive interferon gamma release assay and/or suboptimal titer of anti-RBD IgGs after two doses were the only predictive variables for response to three doses in multivariate analysis. Thus, the standard scheme of vaccination insufficiently protects patients receiving MHD. Anti-RBD IgG and specific CD4+ T cell response after two doses can guide personalized administration of the third dose, which improves the humoral response of SARS-CoV-2 naïve patients receiving MHD., Graphical abstract

Published
2021

17. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Author

Bristol-Myers Squibb, Ono Pharmaceutical, Paz-Ares, Luis, Ramalingam, Suresh S., Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Urban, Laszlo, Bernabé Caro, Reyes, Park, Keunchil, Sakai, Hiroshi, Ohe, Yuichiro, Nishio, Makoto, Audigier-Valette, Clarisse, Burgers, Jacobus A., Pluzanski, Adam, Sangha, Randeep, Gallardo, Carlos, Takeda, Masayuki, Linardou, Helena, Lupinacci, Lorena, Lee, Ki Hyeong, Caserta, Claudia, Provencio, Mariano, Carcereny, Enric, Otterson, Gregory A., Schenker, Michael, Zurawski, Bogdan, Alexandru, Aurelia, Vergnenegre, Alain, Raimbourg, Judith, Feeney, Kynan, Kim, Sang-We, Borghaei, Hossein, O'Byrne, Kenneth J., Hellmann, Matthew D., Memaj, Arteid, Nathan, Faith Ellen, Bushong, Judith, Tran, Phuong, Brahmer, Julie R., Reck, Martin, Bristol-Myers Squibb, Ono Pharmaceutical, Paz-Ares, Luis, Ramalingam, Suresh S., Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Urban, Laszlo, Bernabé Caro, Reyes, Park, Keunchil, Sakai, Hiroshi, Ohe, Yuichiro, Nishio, Makoto, Audigier-Valette, Clarisse, Burgers, Jacobus A., Pluzanski, Adam, Sangha, Randeep, Gallardo, Carlos, Takeda, Masayuki, Linardou, Helena, Lupinacci, Lorena, Lee, Ki Hyeong, Caserta, Claudia, Provencio, Mariano, Carcereny, Enric, Otterson, Gregory A., Schenker, Michael, Zurawski, Bogdan, Alexandru, Aurelia, Vergnenegre, Alain, Raimbourg, Judith, Feeney, Kynan, Kim, Sang-We, Borghaei, Hossein, O'Byrne, Kenneth J., Hellmann, Matthew D., Memaj, Arteid, Nathan, Faith Ellen, Bushong, Judith, Tran, Phuong, Brahmer, Julie R., and Reck, Martin

Abstract

[Introduction] In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) or less than 1% (prespecified descriptive analysis). We report results with minimum 4 years' follow-up., [Methods] Adults with previously untreated stage IV or recurrent NSCLC were randomized (1:1:1) to nivolumab plus ipilimumab, nivolumab, or chemotherapy (PD-L1 ≥1%); or to nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy (PD-L1 <1%). Efficacy included OS and other measures. Safety included timing and management of immune-mediated adverse events (AEs). A post hoc analysis evaluated efficacy in patients who discontinued nivolumab plus ipilimumab due to treatment-related AEs (TRAEs)., [Results] After 54.8 months' median follow-up, OS remained longer with nivolumab plus ipilimumab versus chemotherapy in patients with PD-L1 greater than or equal to 1% (hazard ratio = 0.76; 95% confidence interval: 0.65–0.90) and PD-L1 less than 1% (0.64; 0.51–0.81); 4-year OS rate with nivolumab plus ipilimumab versus chemotherapy was 29% versus 18% (PD-L1 ≥1%); and 24% versus 10% (PD-L1 <1%). Benefits were observed in both squamous and nonsquamous histologies. In a descriptive analysis, efficacy was improved with nivolumab plus ipilimumab relative to nivolumab (PD-L1 ≥1%) and nivolumab plus chemotherapy (PD-L1 <1%). Safety was consistent with previous reports. The most common immune-mediated AE with nivolumab plus ipilimumab, nivolumab, and nivolumab plus chemotherapy was rash; most immune-mediated AEs (except endocrine events) occurred within 6 months from start of treatment and resolved within 3 months after, mainly with systemic corticosteroids. Patients who discontinued nivolumab plus ipilimumab due to TRAEs had long-term OS benefits, as seen in the all randomized population., [Conclusions] At more than 4 years' minimum follow-up, with all patients off immunotherapy treatment for at least 2 years, first-line nivolumab plus ipilimumab continued to demonstrate durable long-term efficacy in patients with advanced NSCLC. No new safety signals were identified. Immune-mediated AEs occurred early and resolved quickly with guideline-based management. Discontinuation of nivolumab plus ipilimumab due to TRAEs did not have a negative impact on the long-term benefits seen in all randomized patients.

Published
2022

19. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Author

Rosell, Rafael, Carcereny, Enric, Gervais, Radj, Vergnenegre, Alain, Massuti, Bartomeu, Felip, Enriqueta, Palmero, Ramon, Garcia-Gomez, Ramon, Pallares, Cinta, Sanchez, Jose Miguel, Porta, Rut, Cobo, Manuel, Garrido, Pilar, Longo, Flavia, Moran, Teresa, Insa, Amelia, De Marinis, Filippo, Corre, Romain, Bover, Isabel, Illiano, Alfonso, Dansin, Eric, de Castro, Javier, Milella, Michele, Reguart, Noemi, Altavilla, Giuseppe, Jimenez, Ulpiano, Provencio, Mariano, Moreno, Miguel Angel, Terrasa, Josefa, Muñoz-Langa, Jose, Valdivia, Javier, Isla, Dolores, Domine, Manuel, Molinier, Olivier, Mazieres, Julien, Baize, Nathalie, Garcia-Campelo, Rosario, Robinet, Gilles, Rodriguez-Abreu, Delvys, Lopez-Vivanco, Guillermo, Gebbia, Vittorio, Ferrera-Delgado, Lioba, Bombaron, Pierre, Bernabe, Reyes, Bearz, Alessandra, Artal, Angel, Cortesi, Enrico, Rolfo, Christian, Sanchez-Ronco, Maria, Drozdowskyj, Ana, Queralt, Cristina, de Aguirre, Itziar, Ramirez, Jose Luis, Sanchez, Jose Javier, Molina, Miguel Angel, Taron, Miquel, and Paz-Ares, Luis

Published
2012
Full Text
View/download PDF

23. Biomarkers in lung oncology

Author

Rosell, Rafael, Vergnenegre, Alain, Liu, Baorui, Cobo, Manuel, Massuti, Bartomeu, Wei, Jia, Molina, Miguel Angel, Costa, Carlota, Queralt, Cristina, and Taron, Miquel

Published
2010
Full Text
View/download PDF

24. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Author

Karachaliou, Niki, Mayo-de las Casas, Clara, Queralt, Cristina, de Aguirre, Itziar, Melloni, Boris, Cardenal, Felipe, Garcia-Gomez, Ramon, Massuti, Bartomeu, Sánchez, José Miguel, Porta, Ruth, Ponce-Aix, Santiago, Moran, Teresa, Carcereny, Enric, Felip, Enriqueta, Bover, Isabel, Insa, Amelia, Reguart, Noemí, Isla, Dolores, Vergnenegre, Alain, de Marinis, Filippo, Gervais, Radj, Corre, Romain, Paz-Ares, Luis, Morales-Espinosa, Daniela, Viteri, Santiago, Drozdowskyj, Ana, Jordana-Ariza, Núria, Ramirez-Serrano, Jose Luis, Molina-Vila, Miguel Angel, and Rosell, Rafael

Published
2015
Full Text
View/download PDF

25. A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an Early Modification of Chemotherapy Doublet with Paclitaxel-Gemcitabine Versus Continuation of Cisplatin-Gemcitabine Chemotherapy (GFPC 03-01 Study)

Author

Vergnenègre, Alain, Tillon, Julie, Corre, Romain, Barlési, Fabrice, Berard, Henri, Vernejoux, Jean-Marc, Le Caer, Hervé, Fournel, Pierre, Marin, Benoit, and Chouaïd, Christos

Published
2009
Full Text
View/download PDF

26. Two-Stage Bronchoscopic Endobronchial Valve Treatment Can Lead to Progressive Lung Volume Reduction and May Decrease Pneumothorax Risk

Author

Egenod,Thomas, Tricard,Jeremy, Fumat,Romane, Simonneau,Yannick, Favard,Florent, Guillot,Marc-Samir, Collot,Samia, Dupuis,Marion, Melloni,Boris, Vergnenegre,Alain, Guibert,Nicolas, Dusselier,Matthieu, Egenod,Thomas, Tricard,Jeremy, Fumat,Romane, Simonneau,Yannick, Favard,Florent, Guillot,Marc-Samir, Collot,Samia, Dupuis,Marion, Melloni,Boris, Vergnenegre,Alain, Guibert,Nicolas, and Dusselier,Matthieu

Abstract

Thomas Egenod,1 Jeremy Tricard,2 Romane Fumat,3 Yannick Simonneau,1 Florent Favard,4 Marc-Samir Guillot,5 Samia Collot,6 Marion Dupuis,3 Boris Melloni,1 Alain Vergnenegre,1 Nicolas Guibert,3 Matthieu Dusselier1 1Pulmonology Department, Dupuytren University Hospital, Limoges, France; 2Thoracic Surgery Department, Dupuytren University Hospital, Limoges, France; 3Pulmonology Department, Toulouse University Hospital, Toulouse, France; 4Physiology Department, Dupuytren University Hospital, Limoges, France; 5Radiology Department, Dupuytren University Hospital, Limoges, France; 6Radiology Department, Toulouse University Hospital, Toulouse, FranceCorrespondence: Thomas EgenodPulmonology Department, Dupuytren University Hospital, Limoges, FranceTel +33 5 55 05 68 92Fax +33 5 55 05 68 15Email thomas.egenod@chu-limoges.frBackground: Since successful development of endobronchial valves (EBV) as treatment for severe emphysema, its main complication, pneumothorax, remains an important concern.Objective: We hypothesized that a two-step EBV implantation, during two distinct iterative procedures could lead to a more progressive target lobe volume reduction (TLVR) and thus ipsilateral lobe re-expansion, resulting in a significant decrease in the pneumothorax rate.Methods: This retrospective bi-center study carried out by Limoges and Toulouse University Hospitals included patients following the inclusion criteria established by the BLVR expert panel. All patients were treated by two distinct procedures: first, EBVs were placed in all but the most proximal segment or sub-segment. The remaining segment was treated subsequently. All patients had a complete evaluation before treatment, and 3 months after the second procedure.Results: Out of 58 patients included, only 4 pneumothoraxes (7%) occurred during the study. The other complications were pneumonia and severe COPD exacerbation (8.6% and 13.7% of patients, respectively). Significant improvement was found for FEV1 (+19.6 ± 25%), RV (â

Published
2021

27. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Author

Karachaliou, Niki, Codony-Servat, Jordi, Teixidó, Cristina, Pilotto, Sara, Drozdowskyj, Ana, Codony-Servat, Carles, Giménez-Capitán, Ana, Molina-Vila, Miguel Angel, Bertrán-Alamillo, Jordi, Gervais, Radj, Massuti, Bartomeu, Morán, Teresa, Majem, Margarita, Felip, Enriqueta, Carcereny, Enric, García-Campelo, Rosario, Viteri, Santiago, González-Cao, María, Morales-Espinosa, Daniela, Verlicchi, Alberto, Crisetti, Elisabetta, Chaib, Imane, Santarpia, Mariacarmela, Luis Ramírez, José, Bosch-Barrera, Joaquim, Felipe Cardona, Andrés, de Marinis, Filippo, López-Vivanco, Guillermo, Miguel Sánchez, José, Vergnenegre, Alain, Sánchez Hernández, José Javier, Sperduti, Isabella, Bria, Emilio, and Rosell, Rafael

Published
2015
Full Text
View/download PDF

28. Two-Stage Bronchoscopic Endobronchial Valve Treatment Can Lead to Progressive Lung Volume Reduction and May Decrease Pneumothorax Risk

Author

Egenod, Thomas, primary, Tricard, Jeremy, additional, Fumat, Romane, additional, Simonneau, Yannick, additional, Favard, Florent, additional, Guillot, Marc-Samir, additional, Collot, Samia, additional, Dupuis, Marion, additional, Melloni, Boris, additional, Vergnenegre, Alain, additional, Guibert, Nicolas, additional, and Dusselier, Matthieu, additional

Published
2021
Full Text
View/download PDF

33. Nivolumab (N) + Low-Dose Ipilimumab (I) vs Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment (tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Checkmate 227 Part 1 Final Analysis

Author

Reck, Martin, Peters, Solange, Ramalingam, Suresh S., Paz-Ares, Luis G., Bernabe Caro, Reyes, Zurawski, Bogdan, Kim, Sang We, Alexandru, Aurelia, Lupinacci, Lorena, de la Mora Jitnenez, Emmanuel, Sakai, Hiroshi, Albert, István, Vergnenegre, Alain, Borghaei, Hossein, Brahmer, Julie, O'Byrne, Ken, Geese, William J., Bhagavatheeswaran, Prabhu, Nattan, Faith E., Hellmann, Matthew D., Reck, Martin, Peters, Solange, Ramalingam, Suresh S., Paz-Ares, Luis G., Bernabe Caro, Reyes, Zurawski, Bogdan, Kim, Sang We, Alexandru, Aurelia, Lupinacci, Lorena, de la Mora Jitnenez, Emmanuel, Sakai, Hiroshi, Albert, István, Vergnenegre, Alain, Borghaei, Hossein, Brahmer, Julie, O'Byrne, Ken, Geese, William J., Bhagavatheeswaran, Prabhu, Nattan, Faith E., and Hellmann, Matthew D.

Abstract

Background Part 1 of CheckMate 227 (NCT02477826), a phase III study in 1L NSCLC, has dual primary endpoints. The primary endpoint of progression-free survival (PFS) with NIVO + IPI vs chemo in patients (pts) with tumor mutational burden ≥ 10 mut/Mb was met, as reported previously. Here we present the primary endpoint of overall survival (OS) for NIVO + IPI vs chemo in pts with tumor PD-L1 expression ≥ 1%. MethodsPts were chemo-naive, with stage IV or recurrent NSCLC without EGFR or known ALK alterations, ECOG PS 0–1. Pts with PD-L1 ≥1% (n = 1189) were randomized 1:1:1 to NIVO 3 mg/kg Q2W + IPI 1 mg/kg Q6W, NIVO 240 mg Q2W, or histology-based chemo; pts with PD-L1 < 1% (n = 550) were randomized 1:1:1 to NIVO 3 mg/kg Q2W + IPI 1 mg/kg Q6W, NIVO 360 mg Q3W + chemo, or chemo. Pts were stratified by histology in both populations. Pts were treated until disease progression, unacceptable toxicity, or for 2 y of immunotherapy. Results Baseline characteristics were balanced across tx arms. Minimum follow-up for the primary endpoint was 29.3 mo. For pts with PD-L1 ≥ 1%, OS was significantly longer with NIVO + IPI vs chemo (HR 0.79, 97.72% CI: 0.65–0.96; P = 0.007); PFS, objective response rates, and duration of response favored NIVO + IPI vs chemo. OS benefit was also observed in pts with PD-L1 < 1% and all randomized pts (Table). Prespecified analyses showed enhanced efficacy with NIVO + IPI relative to NIVO in PD-L1 ≥ 1% and relative to NIVO + chemo in PD-L1 < 1%. Grade 3–4 tx-related adverse event rates in all randomized pts were 33% (N1+1), 19% (N), and 36% (chemo). Conclusions CheckMate 227 met its primary endpoint of significantly improved OS with NIVO + IPI vs chemo in 1L advanced NSCLC with PD-L1 ≥ 1%. OS was also improved with NIVO + IPI in PD-L1 < 1% and in all randomized pts. Safety profile was consistent with previous reports in NSCLC. NIVO + IPI represents a new chemo-free tx option for pts in 1L advanced NSCLC.

Published
2020

35. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Author

Herbst, Roy S., primary, Giaccone, Giuseppe, additional, de Marinis, Filippo, additional, Reinmuth, Niels, additional, Vergnenegre, Alain, additional, Barrios, Carlos H., additional, Morise, Masahiro, additional, Felip, Enriqueta, additional, Andric, Zoran, additional, Geater, Sarayut, additional, Özgüroğlu, Mustafa, additional, Zou, Wei, additional, Sandler, Alan, additional, Enquist, Ida, additional, Komatsubara, Kimberly, additional, Deng, Yu, additional, Kuriki, Hiroshi, additional, Wen, Xiaohui, additional, McCleland, Mark, additional, Mocci, Simonetta, additional, Jassem, Jacek, additional, and Spigel, David R., additional

Published
2020
Full Text
View/download PDF

36. Assessment of preoperative noninvasive ventilation before lung cancer surgery: The preOVNI randomized controlled study

Author

Paleiron, Nicolas, primary, Grassin, Frédéric, additional, Lancelin, Christophe, additional, Tromeur, Cécile, additional, Margery, Jacques, additional, Natale, Claudia, additional, Couturaud, Francis, additional, Gut-Gobert, Christophe, additional, Barnier, Aude, additional, Noël-Savina, Elise, additional, Bazire, Amélie, additional, Payet, Annabelle, additional, Paleiron, Nicolas, additional, Berard, Henri, additional, Andre, Michel, additional, Vaylet, Fabien, additional, Vinas, Florent, additional, Chouaïd, Christos, additional, Venissac, Nicolas, additional, Donzel-Raynaud, Christine, additional, RAUT, Yvonnick, additional, Salley, Nicolas, additional, Corre, Romain, additional, Kerjouan, Mallorie, additional, Cuvelier, Antoine, additional, Gounane, Cherifa, additional, Blandin, Sonia, additional, Falchero, Lionel, additional, Le Treut, Jacques, additional, Aze, Olivier, additional, Gagnadoux, Frédéric, additional, Trzepizur, Wojciech, additional, Vergnenegre, Alain, additional, Egenod, Thomas, additional, Tiffet, Olivier, additional, and Parietti, Eric, additional

Published
2020
Full Text
View/download PDF

39. Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study

Author

Descourt, Renaud, Vergnenegre, Alain, Barlesi, Fabrice, Lena, Herve, Fournel, Pierre, Falchero, Lionel, Berard, Henri, Hureaux, Jose, Le Caer, Herve, Chavaillon, Jean Michel, Geriniere, Laurence, Monnet, Isabelle, Chouabe, Stéphane, and Robinet, Gilles

Published
2011
Full Text
View/download PDF

41. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

Author

Karachaliou, Niki, Bracht, Jillian Wilhelmina Paulina, Fernandez Bruno, Manuel, Drozdowskyj, Ana, Gimenez Capitan, Ana, Moran, Teresa, Carcereny, Enric, Cobo, Manuel, Domine, Manuel, Chaib, Imane, Ramirez, Jose Luis, Camps, Carlos, Provencio, Mariano, Vergnenegre, Alain, Lopez-Vivanco, Guillermo, Majem, Margarita, Massuti, Bartomeu, and Rosell, Rafael

Published
2019
Full Text
View/download PDF

42. Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227

Author

Borghaei, Hossein, primary, Pluzanski, Adam, additional, Caro, Reyes Bernabe, additional, Provencio, Mariano, additional, Burgers, Sjaak, additional, Carcereny, Enric, additional, Park, Keunchil, additional, Alexandru, Aurelia, additional, Lupinacci, Lorena, additional, Sangha, Randeep, additional, Raimbourg, Judith, additional, Vergnenegre, Alain, additional, Syrigos, Konstantinos, additional, Barlesi, Fabrice, additional, Frickhofen, Norbert, additional, Li, Ang, additional, Kasinathan, Ravi, additional, and Paz-Ares, Luis, additional

Published
2020
Full Text
View/download PDF

44. O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC

Author

Herbst, Roy, primary, Marinis, Filippo De, additional, Giaccone, Giuseppe, additional, Reinmuth, Niels, additional, Vergnenegre, Alain, additional, Barrios, Carlos, additional, Morise, Masahiro, additional, Font, Enriqueta, additional, Andric, Zoran, additional, Geater, Sarayut, additional, Ozguroglu, Mustafa, additional, Mocci, Simonetta, additional, McCleland, Mark, additional, Enquist, Ida, additional, Komatsubara, Kim, additional, Deng, Yu, additional, Kuriki, Hiroshi, additional, Wen, Xiaohui, additional, Jassem, Jacek, additional, and Spigel, David, additional

Published
2020
Full Text
View/download PDF

45. Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine–atezolizumab combination for stage-IV non-small-cell lung cancer – VinMetAtezo trial, (GFPC‡ 04-2017)

Author

Vergnenegre, Alain, primary, Monnet, Isabelle, additional, Bizieux, Acya, additional, Bernardi, Marie, additional, Chiapa, Anne Marie, additional, Léna, Hervé, additional, Chouaïd, Christos, additional, and Robinet, Gilles, additional

Published
2020
Full Text
View/download PDF

46. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Author

Hellmann, Matthew D., primary, Paz-Ares, Luis, additional, Bernabe Caro, Reyes, additional, Zurawski, Bogdan, additional, Kim, Sang-We, additional, Carcereny Costa, Enric, additional, Park, Keunchil, additional, Alexandru, Aurelia, additional, Lupinacci, Lorena, additional, de la Mora Jimenez, Emmanuel, additional, Sakai, Hiroshi, additional, Albert, Istvan, additional, Vergnenegre, Alain, additional, Peters, Solange, additional, Syrigos, Konstantinos, additional, Barlesi, Fabrice, additional, Reck, Martin, additional, Borghaei, Hossein, additional, Brahmer, Julie R., additional, O’Byrne, Kenneth J., additional, Geese, William J., additional, Bhagavatheeswaran, Prabhu, additional, Rabindran, Sridhar K., additional, Kasinathan, Ravi S., additional, Nathan, Faith E., additional, and Ramalingam, Suresh S., additional

Published
2019
Full Text
View/download PDF

48. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

Author

Hellmann, Matthew D. Paz-Ares, Luis Bernabe Caro, Reyes Zurawski, Bogdan Kim, Sang-We Carcereny Costa, Enric Park, Keunchil Alexandru, Aurelia Lupinacci, Lorena de la Mora Jimenez, Emmanuel Sakai, Hiroshi Albert, Istvan Vergnenegre, Alain Peters, Solange Syrigos, Konstantinos Barlesi, Fabrice Reck, Martin Borghaei, Hossein Brahmer, Julie R. O'Byrne, Kenneth J. Geese, William J. Bhagavatheeswaran, Prabhu Rabindran, Sridhar K. Kasinathan, Ravi S. Nathan, Faith E. Ramalingam, Suresh S.

Abstract

BACKGROUND: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1\% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1\% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1\% or more. RESULTS: Among the patients with a PD-L1 expression level of 1\% or more, the median duration of overall survival was 17.1 months (95\% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95\% CI, 12.7 to 16.7) with chemotherapy (P = 0.007), with 2-year overall survival rates of 40.0\% and 32.8\%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1\%, with a median duration of 17.2 months (95\% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95\% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95\% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95\% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8\% with nivolumab plus ipilimumab and 36.0\% with chemotherapy. CONCLUSIONS: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).

Published
2019

49. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Author

Bristol-Myers Squibb, Ono Pharmaceutical, Hellmann, Matthew D., Paz-Ares, Luis, Bernabé Caro, Reyes, Zurawski, Bogdan, Kim, Sang-We, Carcereny Costa, Enric, Park, Keunchil, Alexandru, Aurelia, Lupinacci, Lorena, Mora Jiménez, Emmanuel de la, Sakai, Hiroshi, Albert, Istvan, Vergnenegre, Alain, Peters, Solange, Syrigos, Konstantinos, Barlesi, Fabrice, Reck, Martin, Borghaei, Hossein, Brahmer, Julie R., O'Byrne, Kenneth J., Geese, William J., Bhagavatheeswaran, Prabhu, Rabindran, Sridhar K., Kasinathan, Ravi S., Nathan, Faith Ellen, Ramalingam, Suresh S., Bristol-Myers Squibb, Ono Pharmaceutical, Hellmann, Matthew D., Paz-Ares, Luis, Bernabé Caro, Reyes, Zurawski, Bogdan, Kim, Sang-We, Carcereny Costa, Enric, Park, Keunchil, Alexandru, Aurelia, Lupinacci, Lorena, Mora Jiménez, Emmanuel de la, Sakai, Hiroshi, Albert, Istvan, Vergnenegre, Alain, Peters, Solange, Syrigos, Konstantinos, Barlesi, Fabrice, Reck, Martin, Borghaei, Hossein, Brahmer, Julie R., O'Byrne, Kenneth J., Geese, William J., Bhagavatheeswaran, Prabhu, Rabindran, Sridhar K., Kasinathan, Ravi S., Nathan, Faith Ellen, and Ramalingam, Suresh S.

Abstract

[Background] In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC., [Methods] In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more., [Results] Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P=0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy., [Conclusions] First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826. opens in new tab.)

Published
2019

50. Economic analyses of immune-checkpoint inhibitors to treat lung cancer.

Author

Vergnenegre, Alain and Chouaid, Christos

Abstract

Introduction: Total lung-cancer–management costs are increasing dramatically. The widespread use of immune-checkpoint inhibitors (ICIs) explains this rise in large part and financially impacts healthcare systems. Economic assessment has been adapted to this new challenge. Areas covered: This review provides an overview of the economic literature on the use of ICIs to treat lung cancer. Numerous papers have been published over the last few years. Cancers analyzed were non-squamous non-small-cell lung cancer (NSCLC), squamous NSCLC, locally advanced NSCLC, or small-cell lung cancer. Expert commentary: For the majority of patients, ICIs are cost-effective for lung cancer management. However, these results are influenced by the threshold chosen by each of the different countries. Patient selection, treatment duration, and factors predictive of efficacy are mandatory to decrease costs. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results